Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Drug repurposing for yellow fever using high content screening

Denise R. B. Pilger, View ORCID ProfileCarolina B. Moraes, View ORCID ProfileLaura H. V. Gil, Lucio H. Freitas-Junior
doi: https://doi.org/10.1101/225656
Denise R. B. Pilger
1Instituto Butantan, São Paulo-SP, Brazil
2Departmento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
3Laboratório Nacional de Biociências (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM), Campinas, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina B. Moraes
1Instituto Butantan, São Paulo-SP, Brazil
2Departmento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carolina B. Moraes
Laura H. V. Gil
4CPqAM-Fiocruz, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura H. V. Gil
Lucio H. Freitas-Junior
1Instituto Butantan, São Paulo-SP, Brazil
2Departmento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
3Laboratório Nacional de Biociências (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM), Campinas, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: luciofreitasjunior@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

ABSTRACT

Background Yellow fever is an acute febrile illness caused by a mosquito-borne flavivirus. The discovery that mosquitos were responsible for transmission and that the disease was preventable by vector control, as well as the development of an efficacious vaccine (in the 1930s) have reduced its public health impact. However, underutilization of vaccination and discontinuation of vector control measures have led to yellow fever outbreaks, affecting thousands of people in Africa and South America, and is a continued threat to people who travel to endemic regions without vaccination. An additional concern is that the vaccine has important contraindications, and the currently available doses are insufficient to immunize the populations under risk of contracting yellow fever. Specific antiviral chemotherapy would be an alternative to vaccination, however there is none yet available. Drug repurposing is one strategy that can speed up drug discovery and development and has been underexplored for yellow fever.

Methods A high content screening assay for the discovery of anti-yellow fever compounds was developed and used to screen a library of pharmacologically compounds, which includes approved drugs and covers most signalling pathways and all major drug target classes. The same library was screened against cells infected with a serotype 2 of the dengue virus.

Results and conclusion From 1280 compounds screened, 88 compounds (6,9% of the library) were found to reduce yellow fever virus (YFV) infection in 50% or more. Interestingly, the number of compounds that presented similar activity against dengue (DENV) infection was considerably lower (18 compounds, 1,4%). Among these, 12 compounds were active against both viruses, highlighting the potential of finding compounds with broad antiviral activity in diversity libraries. The top 27 anti-YFV compounds were selected for further activity determination in dose-response. Five compounds (Gant61, benztropine mesylate, brequinar sodium salt hydrate, PF-429242 dihydrochloride and U-73343) presented selective activity against YFV infection in a human cell line, but only two of them, brequinar and U-73343, were also active against DENV. These compounds, which represent a broad spectrum of pharmacological functions, have not been previously described as having anti-YFV activity, thus offering a valuable opportunity for the development of specific antiviral chemotherapy for yellow fever.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 27, 2017.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Drug repurposing for yellow fever using high content screening
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Drug repurposing for yellow fever using high content screening
Denise R. B. Pilger, Carolina B. Moraes, Laura H. V. Gil, Lucio H. Freitas-Junior
bioRxiv 225656; doi: https://doi.org/10.1101/225656
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Drug repurposing for yellow fever using high content screening
Denise R. B. Pilger, Carolina B. Moraes, Laura H. V. Gil, Lucio H. Freitas-Junior
bioRxiv 225656; doi: https://doi.org/10.1101/225656

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Microbiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4672)
  • Biochemistry (10340)
  • Bioengineering (7658)
  • Bioinformatics (26300)
  • Biophysics (13501)
  • Cancer Biology (10672)
  • Cell Biology (15413)
  • Clinical Trials (138)
  • Developmental Biology (8487)
  • Ecology (12806)
  • Epidemiology (2067)
  • Evolutionary Biology (16831)
  • Genetics (11382)
  • Genomics (15469)
  • Immunology (10603)
  • Microbiology (25182)
  • Molecular Biology (10210)
  • Neuroscience (54383)
  • Paleontology (399)
  • Pathology (1667)
  • Pharmacology and Toxicology (2889)
  • Physiology (4334)
  • Plant Biology (9235)
  • Scientific Communication and Education (1586)
  • Synthetic Biology (2555)
  • Systems Biology (6773)
  • Zoology (1461)